Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

carilion materials management - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 3 mg - budesonide capsules (enteric coated) are indicated for the treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon. budesonide capsules (enteric coated) are indicated for the maintenance of clinical remission of mild to moderate crohn’s disease involving the ileum and/or the ascending colon for up to 3 months. budesonide capsules (enteric coated) are contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of budesonide capsules (enteric coated). anaphylactic reactions have occurred [ ]. see adverse reactions (6.2) budesonide was teratogenic and embryocidal in rabbits and rats. budesonide produced fetal loss, decreased pup weights, and skeletal abnormalities at subcutaneous doses of 25 mcg/kg in rabbits (approximately 0.05 times the maximum recommended human dose on a body surface area basis) and 500 mcg/kg in rats (approximately 0.5 times the maximum recommended human dose

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

te arai biofarma limited - budesonide 3mg - modified release capsule - 3 mg - active: budesonide 3mg excipient: gelatin   ethylcellulose dispersion type b ink black 10a2 iron oxide black iron oxide red methacrylic acid copolymer polysorbate 80 purified talc sugar spheres titanium dioxide   triethyl citrate - indicated for the induction of remission in patients with mild to moderate crohn's disease affecting the ileum and/or the ascending colon.

Malta - anglų - Medicines Authority

kleva s.a. 189 parnithos avenue, 13671 acharnai, attiki, greece - budesonide - nasal spray, suspension - budesonide 100 µg - nasal preparations

Malta - anglų - Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - budesonide - nebuliser suspension - budesonide 0.25 mg/ml - drugs for obstructive airway diseases

Malta - anglų - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - budesonide - nebuliser suspension - budesonide 0.25 mg - drugs for obstructive airway diseases

Malta - anglų - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - budesonide - nebuliser suspension - budesonide 0.5 mg - drugs for obstructive airway diseases

Malta - anglų - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - budesonide - nebuliser suspension - budesonide 1 mg - drugs for obstructive airway diseases

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

american health packaging - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide delayed-release capsules (enteric coated) are indicated for the treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon in patients 8 years of age and older. budesonide delayed-release capsules (enteric coated) are indicated for the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum and/or the ascending colon for up to 3 months in adults. budesonide capsules (enteric coated) are contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of budesonide capsules (enteric coated). serious hypersensitivity reactions, including anaphylaxis have occurred [see adverse reactions (6.2)]. risk summary limited published studies report on the use of budesonide in pregnant women; however, the data are insufficient to inform a drug-associated risk for major birth defects and miscarriage. there are clinical considerations [see clinical considerations]. in animal re

Airija - anglų - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - budesonide - nebuliser suspension - 1 mg/2ml - glucocorticoids; budesonide

Airija - anglų - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - budesonide - nebuliser suspension - 0.5 mg/2ml - glucocorticoids; budesonide